Acquisition of pluvicto and lutathera for radiology patients.
Ended Purchase Order Awarded Last action
- Contract number
- HT001426PE027
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $578,754
Award facts
- Contract value 100% obligated
- $578,754.32 Current and potential, with all options
- Completion date
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20889, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded a $578,754.32 firm fixed-price purchase order to Novartis Pharmaceuticals Corporation for the acquisition of PLUVICTO (Lutetium Lu-177 Vipivotide Tetra) and LUTATHERA (Lutetium Lu-177 dotatate) to support radiology patients at the performance location in Bethesda, Maryland. The contract has an ultimate completion date of January 15, 2026, with no small business set-aside designation. This award is issued under Novartis' existing Indefinite Delivery Contract with the Defense Health Agency, which was established on October 1, 2024, with a ceiling value of $26.1 million and extends through September 30, 2029, for the procurement of cancer therapy drugs and radiopharmaceuticals.
Novartis Pharmaceuticals Corporation, a large foreign-owned pharmaceutical manufacturer headquartered in East Hanover, New Jersey, is a major federal supplier of specialized oncology treatments and radiopharmaceutical products to the Department of Veterans Affairs and the Defense Health Agency. PLUVICTO and LUTATHERA are advanced nuclear medicine treatments designed for cancer therapy applications within federal healthcare systems. The firm fixed-price structure and direct competition without small business protections reflect Novartis' status as a large manufacturer capable of supplying specialized pharmaceutical products across the federal marketplace.
Quick answers
Who was awarded contract HT001426PE027?
HT001426PE027 was awarded to Novartis Pharmaceuticals Corporation by Defense Health Agency (Department of Defense) on January 15, 2026.
How much is contract HT001426PE027 worth?
The government has obligated $578,754 on HT001426PE027.
Was contract HT001426PE027 competed?
The extent of competition for HT001426PE027 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award